Renin angiotensin system deregulation as renal cancer risk factor (Review)

Oncology Letters

Volumn 14, Issue 5, 2017, Pages 5059-5068

  Sobczuk, Pawel ^a,b   Szczylik, Cezary ^a   Porta, Camillo ^c,d   Czarnecka, Anna M ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d Italian Group of Onco Nephrology (GION)   (Italy)

Author keywords

ACEI; Angiotensin converting enzyme; Hypertension; RCC; Renal cancer

Indexed keywords

ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN II [3-8]; ANGIOTENSIN III; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BEVACIZUMAB; BRADYKININ; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LISINOPRIL; LOSARTAN; PERINDOPRIL; RAMIPRIL; SUNITINIB; TELMISARTAN; VALSARTAN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER MORTALITY; CANCER RISK; CARCINOGENESIS; CELL MIGRATION; DEREGULATION; DISEASE SPECIFIC SURVIVAL; DNA POLYMORPHISM; ENZYME ACTIVITY; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MALE INFERTILITY; META ANALYSIS (TOPIC); NONHUMAN; ORGANOGENESIS; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TUMOR GROWTH; WESTERN BLOTTING; XENOGRAFT;

EID: 85030168831     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2017.6826     Document Type: Review

References (78)

1. Motzer RJ, Bander NH and Nanus DM: Renal-cell carcinoma. N Engl J Med 335: 865-875, 1996.
2. Lopez-Beltran A, Scarpelli M, Montironi R and Kirkali Z: 2004 WHO classification of the renal tumors of the adults. Eur Urol 49: 798-805, 2006.
3. Brodaczewska KK, Szczylik C, Fiedorowicz M, Porta C and Czarnecka AM: Choosing the right cell line for renal cell cancer research. Mol Cancer 15: 83, 2016.
4. Rydzanicz M, Wrzesinski T, Bluyssen HA and Wesoly J: Genomics and epigenomics of clear cell renal cell carcinoma: Recent developments and potential applications. Cancer Lett 341: 111-126, 2013.
5. George AJ, Thomas WG and Hannan RD: The renin-angiotensin system and cancer: Old dog, new tricks. Nat Rev Cancer 10: 745-759, 2010.
6. Miyajima A, Kosaka T, Kikuchi E and Oya M: Renin-angiotensin system blockade: Its contribution and controversy. Int J Urol 22: 721-730, 2015.
7. Wegman-Ostrosky T, Soto-Reyes E, Vidal-Millán S and Sánchez-Corona J: The renin-angiotensin system meets the hallmarks of cancer. J Renin Angiotensin Aldosterone Syst 16: 227-233, 2015.
8. Derosa L, Izzedine H, Albiges L and Escudier B: Hypertension and angiotensin system inhibitors in patients with metastatic renal cell carcinoma. Oncol Rev 10: 298, 2016.
9. Yin G, Yan C and Berk BC: Angiotensin II signaling pathways mediated by tyrosine kinases. Int J Biochem Cell Biol 35: 780-783, 2003.
10. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, WoolfB, Robison K, JeyaseelanR, et al: A novel angiotensin-converting enzyme-related carboxypep- tidase (ACE2) converts angiotensin I to angiotensin 1- 9. Circ Res 87: E1-E9, 2000.
11. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G and Turner AJ: A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275: 33238-33243, 2000.
12. Zhuo JL and Li XC: New insights and perspectives on intrarenal renin-angiotensin system: Focus on intracrine/intracellular angiotensin II. Peptides 32: 1551-1565, 2011.
13. Norwood VF, Craig MR, Harris JM and Gomez RA: Differential expression of angiotensin II receptors during early renal morpho- genesis. Am J Physiol 272: R662-R668, 1997.
14. Arendshorst WJ, Brännström K and Ruan X: Actions of angiotensin II on the renal microvasculature. J Am Soc Nephrol 10 (Suppl 11): S149-S161, 1999.
15. Matsubara H, Sugaya T, Murasawa S, Nozawa Y, Mori Y, Masaki H, Maruyama K, Tsutumi Y, Shibasaki Y, Moriguchi Y, et al: Tissue-specific expression of human angiotensin II AT1 and AT2 receptors and cellular localization of subtype mRNAs in adult human renal cortex using in situ hybridization. Nephron 80: 25-34, 1998.
16. Goldfarb DA, Diz DI, Tubbs RR, Ferrario CM and Novick AC: Angiotensin II receptor subtypes in the human renal cortex and renal cell carcinoma. J Urol 151: 208-213, 1994.
17. Chatterjee PK, Weerackody RP, Mistry SK, Hawksworth GM and McLay JS: Selective antagonism of the AT1 receptor inhibits angiotensin II stimulated DNA and protein synthesis in primary cultures of human proximal tubular cells. Kidney Int 52: 699-705, 1997.
18. Cao Z, Kelly DJ, Cox A, Casley D, Forbes JM, Martinello P, Dean R, Gilbert RE and Cooper ME: Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis. Kidney Int 58: 2437-2351, 2000.
19. Dolley-Hitze T, Jouan F, Martin B, Mottier S, Edeline J, Moranne O, Le Pogamp P, Belaud-Rotureau MA, Patard JJ, Rioux-Leclercq N and Vigneau C: Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma? Br J Cancer 103: 1698-1705, 2010.
20. Gonzalez-Villalobos RA, Shen XZ, Bernstein EA, Janjulia T, Taylor B, Giani JF, Blackwell WL, Shah KH, Shi PD, Fuchs S and Bernstein KE: Rediscovering ACE: Novel insights into the many roles of the angiotensin-converting enzyme. J Mol Med (Berl) 91: 1143-1154, 2013.
21. Krege JH, John SW, Langenbach LL, Hodgin JB, Hagaman JR, Bachman ES, Jennette JC, O’Brien DA and Smithies O: Male-female differences in fertility and blood pressure in ACE-deficient mice. Nature 375: 146-148, 1995.
22. Lin C, Datta V, Okwan-Duodu D, Chen X, Fuchs S, Alsabeh R, Billet S, Bernstein KE and Shen XZ: Angiotensin-converting enzyme is required for normal myelopoiesis. FASEB J 25: 1145-1155, 2011.
23. Chappell MC: Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS receptor axis: More than regulation of blood pressure? Hypertension 50: 596-599, 2007.
24. Takada Y, Hiwada K, Yokoyama M, Ochi K, Takeuchi M and Kokubu T: Angiotensin converting enzyme. A possible histologic indicator for human renal cell carcinoma. Cancer 56: 130-133, 1985.
25. Larrinaga G, Pérez I, Sanz B, Blanco L, López JI, Cándenas ML, Pinto FM, Gil J, Irazusta J and Varona A: Angiotensin-converting enzymes (ACE and ACE2) are downregulated in renal tumors. Regul Pept 165: 218-223, 2010.
26. Usmani BA, Janeczko M, Shen R, Mazumdar M, Papandreou CN and Nanus DM: Analysis of the insertion/deletion polymorphism of the human angiotensin converting enzyme (ACE) gene in patients with renal cancer. Br J Cancer 82: 550-552, 2000.
27. de Martino M, Klatte T, Schatzl G, Waldert M, Remzi M, Haitel A, Kramer G and Marberger M: Insertion/deletion polymorphism of angiotensin I-converting enzyme gene is linked with chromophobe renal cell carcinoma. Urology 77: 1005. e9-1005.e13, 2011.
28. van der Knaap R, Siemes C, Coebergh JW, van Duijn CM, Hofman A and Stricker BH: Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism and cancer: The Rotterdam Study. Cancer 112: 748-757, 2008.
29. Deckers IA, van den Brandt PA, van Engeland M, van Schooten FJ, Godschalk RW, Keszei AP and Schouten LJ: Polymorphisms in genes of the renin-angiotensin-aldosterone system and renal cell cancer risk: Interplay with hypertension and intakes of sodium, potassium and fluid. Int J Cancer 136: 1104-1116, 2015.
30. Andreotti G, Boffetta P, Rosenberg PS, Berndt SI, Karami S, Menashe I, Yeager M, Chanock SJ, Zaridze D, Matteev V, et al: Variants in blood pressure genes and the risk of renal cell carci- noma. Carcinogenesis 31: 614-620, 2010.
31. Kohara K, Brosnihan KB and Ferrario CM: Angiotensin(1-7) in the spontaneously hypertensive rat. Peptides 14: 883-891, 1993.
32. Zhu T, Miller AG, Deliyanti D, Berka DR, Agrotis A, Campbell DJ and Wilkinson-Berka JL: Prorenin stimulates a pro-angiogenic and pro-inflammatory response in retinal endothelial cells and an M1 phenotype in retinal microglia. Clin Exp Pharmacol Physiol 42: 537-548, 2015.
33. Shibayama Y, Fujimori T, Nguyen G, Hirose T, Totsune K, Ichihara A, Kitada K, Nakano D, Kobori H, Kohno M, et al: (Pro) renin receptor is crucial for Wnt/β-catenin-dependent genesis of pancreatic ductal adenocarcinoma. Sci Rep 5: 8854, 2015.
34. Trask AJ and Ferrario CM: Angiotensin-(1-7): pharmacology and new perspectives in cardiovascular treatments. Cardiovasc Drug Rev 25: 162-174, 2007.
35. Yacoub R and Campbell KN: Inhibition of RAS in diabetic nephropathy. Int J Nephrol Renovasc Dis 8: 29-40, 2015.
36. Montana V and Sontheimer H: Bradykinin promotes the chemotactic invasion of primary brain tumors. J Neurosci 31: 4858-4867, 2011.
37. Williams RN, Parsons SL, Morris TM, Rowlands BJ and Watson SA: Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models. Eur J Surg Oncol 31: 1042-1050, 2005.
38. de Groot-Besseling RR, Ruers TJ, van Kraats AA, Poelen GJ, Ruiter DJ, de Waal RM and Westphal JR: Anti-tumor activity of a combination of plasminogen activator and captopril in a human melanoma xenograft model. Int J Cancer 112: 329-334, 2004.
39. McMurray J and Chopra M: Influence of ACE inhibitors on free radicals and reperfusion injury: Pharmacological curiosity or therapeutic hope? Br J Clin Pharmacol 31: 373-379, 1991.
40. Zheng S, Yang Y, Song R, Yang X, Liu H, Ma Q, Yang L, Meng R, Tao T, Wang S and He J: Ang-(1-7) promotes the migration and invasion of human renal cell carcinoma cells via Mas-mediated AKT signaling pathway. Biochem Biophys Res Commun 460: 333-340, 2015.
41. Esteban V, Heringer-Walther S, Sterner-Kock A, de Bruin R, van den Engel S, Wang Y, Mezzano S, Egido J, Schultheiss HP, Ruiz-Ortega M and Walther T: Angiotensin-(1-7) and the g protein-coupled receptor MAS are key players in renal inflammation. PLoS One 4: e5406, 2009.
42. Ni L, Feng Y, Wan H, Ma Q, Fan L, Qian Y, Li Q, Xiang Y and Gao B: Angiotensin-(1-7) inhibits the migration and invasion of A549 human lung adenocarcinoma cells through inactivation of the PI3K/Akt and MAPK signaling pathways. Oncol Rep 27: 783-790, 2012.
43. Soto-Pantoja DR, Menon J, Gallagher PE and Tallant EA: Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor. Mol Cancer Ther 8: 1676-1683, 2009.
44. Gallagher PE and Tallant EA: Inhibition of human lung cancer cell growth by angiotensin-(1-7). Carcinogenesis 25: 2045-2052, 2004.
45. Mukai H, Fitzgibbon WR, Bozeman G, Margolius HS and Ploth DW: Bradykinin B2 receptor antagonist increases chloride and water absorption in rat medullary collecting duct. Am J Physiol 271: R352-R360, 1996.
46. Bagaté K, Grima M, Imbs JL, Jong WD, Helwig JJ and Barthelmebs M: Signal transduction pathways involved in kinin B(2) receptor-mediated vasodilation in the rat isolated perfused kidney. Br J Pharmacol 132: 1735-1742, 2001.
47. El-Dahr SS, Dipp S and Baricos WH: Bradykinin stimulates the ERK->Elk-1->Fos/AP-1 pathway in mesangial cells. Am J Physiol 275: F343-F352, 1998.
48. Moodley R, Snyman C, Odhav B and Bhoola KD: Visualisation of transforming growth factor-beta 1, tissue kallikrein, and kinin and transforming growth factor-beta receptors on human clear-cell renal carcinoma cells. Biol Chem 386: 375-382, 2005.
49. Kramarenko II, Morinelli TA, Bunni MA, Raymond JR Sr and Garnovskaya MN: The bradykinin B(2) receptor induces multiple cellular responses leading to the proliferation of human renal carcinoma cell lines. Cancer Manag Res 4: 195-205, 2012.
50. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL and Robertson JW: Do inhibitors of angiotensin-I-converting enzyme protect agains risk of cancer? Lancet 352: 179-184, 1998.
51. Yoon C, Yang HS, Jeon I, Chang Y and Park SM: Use of angio- tensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: A meta-analysis of observational studies. CMAJ 183: E1073-E1084, 2011.
52. Fryzek JP, Poulsen AH, Johnsen SP, McLaughlin JK, Sørensen HT and Friis S: A cohort study of antihypertensive treatments and risk of renal cell cancer. Br J Cancer 92: 1302-1306, 2005.
53. Chin HJ, Oh SW, Goo HS, Oh J, Noh JW, Cho JT, Na KY, Kim S and Chae DW; Members of The PREMIER Group: Effect of RAAS inhibition on the incidence of cancer and cancer mortality in patients with glomerulonephritis. J Korean Med Sci 26: 59-66, 2011.
54. Wysocki PJ, Kwiatkowska EP, Kazimierczak U, Suchorska W, Kowalczyk DW and Mackiewicz A: Captopril, an angiotensin-converting enzyme inhibitor, promotes growth of immunogenic tumors in mice. Clin Cancer Res 12: 4095-4102, 2006.
55. Hii SI, Nicol DL, Gotley DC, Thompson LC, Green MK and Jonsson JR: Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br J Cancer 77: 880-883, 1998.
56. Araujo WF, Naves MA, Ravanini JN, Schor N and Teixeira VP: Renin-angiotensin system (RAS) blockade attenuates growth and metastatic potential of renal cell carcinoma in mice. Urol Oncol 33: 389.e1-e7, 2015.
57. McKay RR, Rodriguez GE, Lin X, Kaymakcalan MD, Hamnvik OP, Sabbisetti VS, Bhatt RS, Simantov R and Choueiri TK: Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Cancer Res 21: 2471-2479, 2015.
58. Tatokoro M, Fujii Y, Kawakami S, Saito K, Koga F, Matsuoka Y, Iimura Y, Masuda H and Kihara K: Phase-II trial of combination treatment of interferon-α, cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin-system inhibitor (I-CCA therapy) for advanced renal cell carcinoma. Cancer Sci 102: 137-143, 2011.
59. Miyajima A, Yazawa S, Kosaka T, Tanaka N, Shirotake S, Mizuno R, Kikuchi E and Oya M: Prognostic impact of renin-angiotensin system blockade on renal cell carcinoma after surgery. Ann Surg Oncol 22: 3751-3759, 2015.
60. Keizman D, Huang P, Eisenberger MA, Pili R, Kim JJ, Antonarakis ES, Hammers H and Carducci MA: Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination. Eur J Cancer 47: 1955-1961, 2011.
61. Izzedine H, Derosa L, Le Teuff G, Albiges L and Escudier B: Hypertension and angiotensin system inhibitors: Impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma. Ann Oncol 26: 1128-1133, 2015.
62. Hamnvik OP, Choueiri TK, Turchin A, McKay RR, Goyal L, Davis M, Kaymakcalan MD and Williams JS: Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer 121: 311-319, 2015.
63. Sorich MJ, Kichenadasse G, Rowland A, Woodman RJ and Mangoni AA: Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials. Int J Cancer 138: 2293-2299, 2016.
64. Penttila P, Rautiola J, Poussa T, Peltola K and Bono P: Angiotensin inhibitors as treatment of Sunitinib/Pazopanib-induced hypertension in metastatic renal cell carcinoma. Clin Genitourin Cancer 15: 384-390.e3, 2017.
65. Huillard O, Xylinas E, Peyromaure M, Alexandre J and Goldwasser F: Angiotensin system inhibitors in renal cell carcinoma-letter. Clin Cancer Res 22: 524, 2016.
66. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, et al: Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42: 1206-1252, 2003.
67. Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, Figlin RA, Baum MS and Motzer RJ: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103: 763-773, 2011.
68. Robinson ES, Khankin EV, Choueiri TK, Dhawan MS, Rogers MJ, Karumanchi SA and Humphreys BD: Supression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. Hypertension 56: 1131-1136, 2010.
69. Gupta R and Maitland ML: Sunitinib, hypertension, and heart failure: A model for kinase inhibitor-mediated cardiotoxicity. Curr Hypertens Rep 13: 430-435, 2011.
70. Kappers MH, van Esch JH, Sluiter W, Sleijfer S, Danser AH and van den Meiracker AH: Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension 56: 675-681, 2010.
71. Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR and O’Dwyer PJ: Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 24: 1363-1369, 2006.
72. Curwen JO, Musgrove HL, Kendrew J, Richmond GH, Ogilvie DJ and Wedge SR: Inhibition of vascular endothelial growth factor-a signaling induces hypertension: Examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy. Clin Cancer Res 14: 3124-3131, 2008.
73. Siddiqui AJ, Mansson-Broberg A, Gustafsson T, Grinnemo KH, Dellgren G, Hao X, Fischer H and Sylvén C: Antagonism of the renin-angiotensin system can counteracts cardiac angiogenic vascular endothelial growth factor gene therapy and myocardial angiogenesis in normal heart. Am J Hyprtens 18: 1347-1352, 2005.
74. Agabiti-Rosei E: Structural and functional changes of the microcirculation in hypertension: Influence of pharmacological therapy. Drugs 63: 19-29, 2003 (In French).
75. Szmit S, Langiewicz P, Zlnierek J, Nurzyński P, Zaborowska M, Filipiak KJ, Opolski G and Szczylik C: Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines. Kidney Blood Press Res 35: 18-25, 2012.
76. Zhu X, Stergiopoulos K and Wu S: Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis. Acta Oncol 48: 9-17, 2009.
77. Nagasawa T, Hye Khan MA and Imig JD: Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib. Clin Exp Pharmacol Physiol 39: 454-461, 2012.
78. Lankhorst S, Kappers MH, van Esch JH, Smedts FM, Sleijfer S, Mathijssen RH, Baelde HJ, Danser AH and van den Meiracker AH: Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: Preclinical study. Hypertension 64: 1282-1289, 2014.